reduction, and their meta-analyses 19 showed a significant 10% risk reduction for overall mortality.
The last important piece of evidence concerned the benefit of BP-lowering drugs on cardiovascular risk even without hypertension. This has been shown by powerful trials such as HOPE 20 in high cardiovascular risk patients, and PROGRESS 21 in stroke survivors, with or without hypertension. Retrospectively, we can observe that this kind of evidence was already present, with the clear benefits observed from beta-blockers and angiotensin converting enzyme inhibitors after myocardial infarction, and in patients with congestive heart failure. Of note in this context, the role of BP lowering in risk reduction has only rarely been offered as an explanation for the effect.
Background of the guidelines evolution regarding BP thresholds The guidelines for BP-lowering drug use followed the development of this knowledge, but with some liberty regarding the definition of hypertension. The initial stress on diastolic BP was enlarged to take systolic into account, necessary to define indications in older hypertensive individuals, in whom low diastolic BP is not only frequent, but also an aggravating risk factor. The reversal of the association between diastolic BP and risk occurs around 60 years of age. 22 The difficulty in translating the complex association between systolic and diastolic BP, age and cardiovascular risk into simple practical rules, is further amplified by the lack of a natural threshold to define hypertension: above 120 mm Hg of systolic BP, all strata display a risk higher than the nearest lower one. 23 As a consequence, this continuous relationship makes all attempts to define hypertension arbitrary. This explains why these thresholds are often called into question, and the cardiovascular risk level approach is often proposed to replace or at least complement them in guidelines. 24 This rapid overview shows that an appropriate level of evidence is only available for hypertensive patients over 60 years of age with a systolic BP of 160 mm Hg and above. There did not seem to be a convincing answer to the question of the benefit-to-risk ratio in mild hypertension, defined by a diastolic BP between 90 and 99 mm Hg, and/or a systolic BP between 140 and 159 mm Hg. Answering this question was the objective of a systematic review published in the Cochrane Library in August 2012.
AN INCREDIBLE LACK OF EVIDENCE FOR BENEFITS ON MILD HYPERTENSION
Reminder of the principal results When looking at all the available evidence, only four trials provided specific data on the primary prevention of mild hypertension, with a total of 8912 participants for total mortality, and 7080 participants for non-fatal and fatal outcomes. None of the outcomes demonstrated a significant benefit of drug therapy compared with placebo: relative risk for total mortality was 0.85 (95% CI: 0.63, 1.15), for coronary heart disease 1.12 (95% CI: 0.80, 1.57), for stroke 0.51 (95% CI: 0.24, 1.08) and for total cardiovascular events 0.97 (95% CI: 0.72, 1.32). Based on the largest trial, the rate of withdrawals because of adverse effects was increased by more than fourfold in the drug therapy group compared with the control (RR: 4.80, 95% CI: 4.14, 5.57); in absolute terms, this means that approximately one patient in ten receiving antihypertensive therapy had an adverse event leading to withdrawal.
Half of the hypertensive population Lowering the threshold definition of hypertension was not examined in the light of its economic aspects. The distribution of risk factors coupled with the age and sex structure of the real French population allowed us to generate a virtual population, with which it was possible to compute that primary prevention mild hypertensive patients make up more than half of the total population of hypertensive patients. 25 This estimate may not be accurate for other populations, but it provides a sense of the order of magnitude of the importance of the group with mild hypertension. Summing up the information from randomized controlled trials in all categories of hypertension gives a statistically significant benefit for all outcomes. Subgroup analyses raise the issue of increasing risks, and both false positives and false negatives. However, the size of this sub-group, representing more than half the eligible population for treatment, is a strong rationale to focus on this principal subgroup.
Treating low-risk people could be a high-risk strategy The most logical way to extrapolate results from clinical trials is using the effect-model law, 26 which describes the risk expected under treatment as a function of the risk without treatment. In cardiovascular prevention, this function is frequently assumed to be a mere multiplication, by a coefficient estimated as the relative risk from a meta-analysis. The absolute benefit is directly proportional to the spontaneous risk, which justifies prioritizing treatment of high-risk people.
For other similar risk factors, mild hypertensive individuals have a lower risk than those with moderate or severe hypertension. They also have a lower expected absolute benefit, which could be more easily counterbalanced with side effects of the treatment, potentially leading to an unfavorable benefit-to-harm balance.
HOW TO DEAL WITH THIS INFORMATION? LET US INFORM PATIENTS!
Editors' and experts' positions about how to deal with such inconclusive results in practice are divergent. [27] [28] [29] The minimum on which all experts must agree is that the physician in charge, must tell the truth to his/her patients regarding the benefit from treatment they are proposing. In this case, they must say that he/ she does not know whether the benefit-to-harm balance is favorable or unfavorable.
In parallel to that information, physicians have to explain that the definitions of hypertension have always been arbitrary, subject to change and do not define high-risk situations by themselves, or situations that are consistently associated with benefit from treatment.
IMPLICATIONS FOR RESEARCH
Some BP-lowering drugs such as b-blockers and ACE inhibitors have been assessed in cardiovascular prevention in high-risk groups, after coronary events, in congestive heart failure, or in patients selected based on the association of several risk factors. In these settings, they have been regularly associated with significant benefit on cardiovascular outcome fatal or not, even in sub-groups of patients without hypertension. The precise role of BP lowering in this risk reduction is a matter of debate. That such drugs could be associated with some benefit in low-risk hypertensive people is possible but not demonstrated today, and is challenged by the low expected absolute benefit. Progress for managing risk in this population is expected from (1) a better understanding of the relationship between individual characteristics and the benefit and side effects of treatment; (2) the availability of tools to display on the physician's desk computer the information on the benefits and the risks from treatment options adjusted to a given patient's profile; (3) increasing the level of evidence regarding the benefit-to-harm ratio of BPlowering drugs in primary prevention mild-hypertension patients. The latter would require conducting a specific clinical trial. One may be tempted to design a treatment withdrawal trial, which could be very useful if it would demonstrate that withdrawal is possible without trouble. However, if such a trial showed a benefit in continuing treatment that would not be equivalent to the required prospective randomized clinical trial. Conducting such a trial is definitely not unethical. Treating millions of patients without knowing whether benefits outweigh harms is obviously far from ethical and is not common sense.
